Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry
Sebastian Raimundo
Naunyn-Schmiedeberg's Archives of Pharmacology, 2004
View PDFchevron_right
Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles
Alessia Bogni
Toxicology in Vitro, 2005
View PDFchevron_right
Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily
Chris Doecke
The Biochemical journal, 1993
View PDFchevron_right
Associate editor: H. Bönisch Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
天鹏 张
View PDFchevron_right
Comparative Metabolic Capabilities and Inhibitory Profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17
Hongwu Shen
Drug Metabolism and Disposition, 2007
View PDFchevron_right
Amodiaquine Clearance and Its Metabolism toN-Desethylamodiaquine Is Mediated by CYP2C8: A New High Affinity and Turnover Enzyme-Specific Probe Substrate
Collen Masimirembwa
Journal of Pharmacology and Experimental Therapeutics, 2002
View PDFchevron_right
Estimation of Drug-Metabolizing Capacity by Cytochrome P450 Genotyping and Expression
E. Sarvary
Journal of Pharmacology and Experimental Therapeutics, 2012
View PDFchevron_right
Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates
Susana Almenara
Biomedicines, 2020
View PDFchevron_right
Decreased Susceptibility of the Cytochrome P450 2B6 Variant K262R to Inhibition by Several Clinically Important Drugs
J. Talakad
Drug Metabolism and Disposition, 2008
View PDFchevron_right
Functional Characterization of Cytochrome P450 2A6 Allelic Variants CYP2A6*15, CYP2A6*16, CYP2A6*21, and CYP2A6*22
Rusli Ismail
Drug Metabolism and Disposition, 2010
View PDFchevron_right
Cytochrome P450 – Role In Drug Metabolism And Genetic Polymorphism
Anitha Rajan
2018
View PDFchevron_right
Functional characterization of eight human cytochrome P450 1A2 gene variants by recombinant protein expression
José Rueff
The Pharmacogenomics Journal, 2010
View PDFchevron_right
Enzyme-Based Amperometric Platform to Determine the Polymorphic Response in Drug Metabolism by Cytochromes P450
Gianfranco Gilardi
Analytical Chemistry, 2011
View PDFchevron_right
Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment
Ivar Roots
Pharmacogenomics, 2000
View PDFchevron_right
Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism
A. Gaedigk
American journal of human genetics, 1991
View PDFchevron_right
Cytochrome P450 Part 2: Genetics of Inter-Individual Variability
Ross McKinnon
Journal of Pharmacy Practice and Research, 2008
View PDFchevron_right
A proposed simple screening method to determine relative contributions of CYP3A4 and CYP3A5 to drug metabolism in vitro
Su Nwe San
Personalized Medicine Universe, 2019
View PDFchevron_right
PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5
John Schuetz
Pharmacological reviews, 2004
View PDFchevron_right
Substrate-Dependent Functional Alterations of Seven CYP2C9 Variants Found in Japanese Subjects
Toshiyuki Miyata
Drug Metabolism and Disposition, 2009
View PDFchevron_right
A rapid and simple LC–MS/MS method for the simultaneous evaluation of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 hydroxylation capacity
Fernando De Andres
Bioanalysis, 2014
View PDFchevron_right
Cytochromes P450 and experimental models of drug metabolism
Eva Anzenbacherova
Journal of Cellular and Molecular Medicine, 2002
View PDFchevron_right
Pharmacogenomic Role in Cytochrome P450 Enzymes-Mediated Metabolism for Drug Therapy
Linawati Hananta
Journal of Urban Health Research
View PDFchevron_right
Genetic Variations in Cytochrome P450 2C9 and 2C19: A Review
abdoljalal marjani
Current Pharmacogenomics and Personalized Medicine, 2017
View PDFchevron_right
Opportunities and obstacles in genotypic prediction of cytochrome P450 phenotypes
Joseph McGraw
Expert Opinion on Drug Metabolism & Toxicology, 2018
View PDFchevron_right
Evidence of Significant Contribution from CYP3A5 to Hepatic Drug Metabolism
Weili Huang
Drug Metabolism and Disposition, 2004
View PDFchevron_right
Determination of Cytochrome P450 Metabolic Activity Using Selective Markers
Alexandra Sulcova
Topics on Drug Metabolism, 2012
View PDFchevron_right
Relative Contributions of CYP3A4 vs. CYP3A5 for CYP3A Cleared Drugs Assessed In Vitro Using a CYP3A4 Selective Inactivator (CYP3cide)
Ricardo Luzietti
Drug Metabolism and Disposition, 2014
View PDFchevron_right
Polymorphic Cytochrome P450 Enzymes (CYPs) and Their Role in Personalized Therapy
Robert Preissner
PLoS ONE, 2013
View PDFchevron_right
Cytochrome P450 3A pharmacogenetics: the road that needs traveled
James Rae
The Pharmacogenomics Journal, 2003
View PDFchevron_right
Identification of human cytochrome P 450 s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data
Mna Hih
European Journal of Clinical Pharmacology, 2003
View PDFchevron_right
Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance
Kathrin Klein
Frontiers in Genetics, 2013
View PDFchevron_right
Rapid and comprehensive determination of cytochrome P450CYP2D6 poor metabolizer genotypes by multiplex polymerase chain reaction
Martin Kennedy
Human Mutation, 2000
View PDFchevron_right
Potential Contribution of Cytochrome P450 2B6 to Hepatic 4-Hydroxycyclophosphamide Formation In Vitro and In Vivo
Rheem Totah
Drug Metabolism and Disposition, 2012
View PDFchevron_right
Structure of cytochrome P450 2C9*2 in complex with an anti-hypertensive drug losartan: Insights into the effect of genetic polymorphism
Juliet Obi
Molecular Pharmacology
View PDFchevron_right
Prediction of CYP2C9-MEDIATED Drug-Drug Interactions: A Comparison Using Data from Recombinant Enzymes and Human Hepatocytes
James Tucker
Drug Metabolism and Disposition, 2005
View PDFchevron_right